Results 301 to 310 of about 122,145 (339)

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.

British Journal of Anaesthesia
Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing dramatically, as indications are expanding from the treatment of diabetes mellitus to weight loss for people with obesity.
M. L. van Zuylen, S. Siegelaar, M. Plummer, Adam M. Deane, J. Hermanides, A. Hulst   +5 more
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function

Heart, Lung and Circulation, 2021
Prevention of cardiovascular events and regression of atherosclerotic changes are the primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by endothelial dysfunction, which disrupts vascular haemostasis. Glucagon-like peptide 1 (GLP-1) receptor agonists have been initially used as glucose lowering agents, but over time have
Edin Begic, Mirsada Causevic
openaire   +2 more sources

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.

The Lancet Diabetes and Endocrinology
BACKGROUND SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not ...
Ellen M Apperloo, B. Neuen, R. Fletcher, N. Jongs, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z. I. Cherney, W. Herrington, S. Inzucchi, M. Jardine, Chih-Chin Liu, Kenneth W Mahaffey, Darren K. Mcguire, John J.V. McMurray, B. Neal, M. Packer, V. Perkovic, M. Sabatine, Scott D. Solomon, N. Staplin, M. Szarek, M. Vaduganathan, Christoph Wanner, David C. Wheeler, S. Wiviott, F. Zannad, H. Heerspink   +27 more
semanticscholar   +1 more source

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources

[The glucagon-like peptide-1 receptor-agonist semaglutide].

Ugeskrift for laeger, 2020
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes.
Amalie Dyhrberg, Boje, Christian Rimer, Juhl, Signe Sørensen, Torekov, Sten, Madsbad   +3 more
openaire   +1 more source

Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

Annals of Pharmacotherapy, 2012
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted in adults.
Kathryn M, Hurren, Nicole R, Pinelli
openaire   +2 more sources

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists

Diabetes, obesity and metabolism
To assess whether adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures who are glucagon‐like peptide‐1 receptor agonist (GLP1‐RA) users, compared with non‐users, are at ...
D. Klonoff, Sun H. Kim, R. J. Galindo, Jeffery I Joseph, V. Garrett, S. Gombar, Rachel E. Aaron, Tiffany Tian, David Kerr   +8 more
semanticscholar   +1 more source

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study

Diabetes, obesity and metabolism
We aimed to investigate the long‐term impact of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on thyroid function, cardiovascular health, renal outcomes and adverse events in individuals with obesity and without type 2 diabetes (T2D).
Yu‐Nan Huang, Wen-Ling Liao, Jing-Yang Huang, Yu-Jung Lin, Shun-Fa Yang, Chieh‐Chen Huang, Chung-Hsing Wang, P. Su   +7 more
semanticscholar   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) show anti‐inflammatory properties.
Aakash Desai, Jessica C Petrov, Jana G. Hashash, Harsh Patel, Bhaumik Brahmbhatt, G. Kochhar, F. Farraye   +6 more
semanticscholar   +1 more source